Erythropoietin Drugs Market Size, Share & Analysis Report, 2025-2034
The erythropoietin drugs market size was exhibited at USD 7.09 billion in 2024 and is projected to hit around USD 8.31 billion by 2034, growing at a CAGR of 1.6% during the forecast period 2025 to 2034.
The U.S. erythropoietin drugs market size is evaluated at USD 2.18 billion in 2024 and is projected to be worth around USD 2.56 billion by 2034, growing at a CAGR of 1.47% from 2025 to 2034.
North America dominated the overall erythropoietin drugs market in terms of the revenue share of 40.35% in 2024. The regional market is anticipated to significantly benefit from local organizations that are actively engaged in advancing the development and use of erythropoietin drugs. Currently, there are five erythropoietin drugs available-NeoRecormon (epoetin beta), Dynepo (epoetin delta), Eprex (epoetin alfa), Aranesp (darbepoetin alfa), and Mircera (methoxy polyethylene glycol-epoetin beta). Biosimilars have been recently introduced in the U.S. market, which is expected to negatively impact market growth.
Asia Pacific is expected to witness a growth rate of 3.0% over the forecast period. The growth of the region is attributed to the presence of key players in the market and strategic initiatives undertaken by them to develop and commercialize new erythropoietin drug products to treat anemia patients. For instance, in September 2021, Wanbang Biopharma received approval for Yi Bao (Human Erythropoietin Injection) from NMPA (National Medical Products Administration). It is indicated to treat chemotherapy-associated anemia in patients with non-myeloid malignancies. All such strategic initiatives are expected to propel market growth in the Asia Pacific region.
| Report Coverage | Details |
| Market Size in 2025 | USD 7.21 Billion |
| Market Size by 2034 | USD 8.31 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 1.6% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Type, Product, Application, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Johnson & Johnson Services, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; LG Chem; Biocon; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd; Dr. Reddy’s Laboratories Ltd |
The biologics segment dominated the drugs market with a revenue share of 55.14% in 2024. This can be attributed to their high usage rate in the U.S. due to the lesser penetration of biosimilars. Erythropoietin biologics include Procrit (Johnson & Johnson), NeoRecormon, Epogin, Mircera (F. Hoffmann La-Roche Ltd.), and Aranesp and Epogen from Amgen. However, this segment is losing its market share and is expected to exhibit a decline over the forecast period.
The biosimilars segment is expected to witness lucrative growth over the forecast period owing to the expiry of major patented drugs in the U.S. The European and APAC markets already have a higher penetration of biosimilars. Some of the major erythropoietin drugs whose patents will expire during the forecast include Aranesp (darbepoetin) and Mircera (PEG-EPO). The company may lose patent rights for this drug by May 2024 (U.S.). Thus, the patent expiration of this drug opens new opportunities for biosimilar manufacturers to develop and commercialize their products.
The erythropoietin segment dominated the erythropoietin drugs market with a revenue share of 77.78% in 2024. According to NCBI, a study was carried out to compare the therapeutic efficacy of Epoetin alfa and Epoetin -beta in hemodialysis patients. It was reported that Epoetin -beta was more effective in maintaining the hemoglobin concentration and that a higher dose of Epoetin -alfa was required to maintain the same hemoglobin concentration. Owing to this improved efficacy, the market for Epoetin -beta is expected to exhibit positive growth.
The Darbepoetin-alfa segment is expected to grow at a high growth rate over the forecast period. The growth of the segment can be attributed to initiatives undertaken by the company to provide financial assistance to patients for purchasing ARANESP (darbepoetin alfa). In the U.S., Amgen, Inc. offers financial assistance to uninsured patients through its Amgen Safety Net Foundation. It is up to public and private reimbursement providers whether they mandate to engage in schemes or not. This foundation also guides insured patients to avail and buy discount benefits associated with Aranesp.
The renal diseases segment dominated the erythropoietin drugs market with a revenue share of 44.0% in 2024. This dominance can be attributed to the fact that the wide availability of erythropoietin drugs for the treatment of patients suffering from different renal disease conditions. Some of the erythropoietin drugs used are Epogen, Aranesp, Venofer, and Ferrlecit. These drugs represent approximately 25% of the total payments of drugs that are used for the management of anemia patients with CKD as per the Medicare and Beneficiary report. Thus, the presence of well-developed reimbursement policies for renal transplants and related diseases is also expected to drive the erythropoietin drugs market.
The cancer segment is expected to witness the fastest growth over the forecast period owing to the disease burden. According to Globocan, the number of new cancer cases is anticipated to reach 28.4 million within the next two decades, with a rise of 47% from 2020, owing to the adoption of a western lifestyle, high consumption of alcohol, smoking, poor diet choices, and physical inactivity. Erythropoietin drugs majorly epoetin-alfa have been in use to increase the hemoglobin levels in cancer patients who have developed chemotherapy-associated anemia. Thus, a growing number of cancer cases is projected to propel the demand for erythropoietin drugs.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Erythropoietin Drugs Market
By Type
By Product
By Application
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers